典型文献
Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small-cell lung cancer:A real-world,multicenter,retrospective,controlled study in China
文献摘要：
Objective:Atezolizumab along with chemotherapy has prolonged the survival of patients with extensive-stage small-cell lung cancer(ES-SCLC)worldwide,although real-world(RW)data are lacking in China.This study was designed to evaluate the efficacy and clinical outcomes of atezolizumab plus etoposide/platinum(EP).Methods:Data obtained in this retrospective study were captured from six oncology units of five medical facilities from January 2019 to April 2022.For first-line treatments,atezolizumab combined with EP vs.EP alone,we primarily evaluated progression-free survival(PFS);other efficacy indicators,including overall survival(OS),objective response rate(ORR),and patterns of SCLC progression and adverse events(AEs)were assessed.Results:The primary analysis included data from 225 patients,of whom 133 received EP along with atezolizumab(atezolizumab group)and 92 received EP alone(EP group).The PFS duration of the atezolizumab group[7.10 months;95％confidence interval(95％CI),6.53-9.00]exceeded that of the EP group(6.50 months;95％CI,4.83-7.53).Overall,the hazard ratio(HR)was 0.69(95％CI,0.49-0.97)(P=0.029);particularly,the HR was 0.54(95％CI,0.36-0.80)among patients undergoing≥4 chemotherapy cycles and 0.33(95％CI,0.20-0.56)among individuals with atezolizumab maintenance.The ORR and disease-control rate(DCR)were similar between the two groups.Because of incomplete OS data,the median OS was not determined for either group.Bone marrow suppression was the most common AE detected(58.6％)in the atezolizumab group.Immune-related AEs occurred in 19 patients in the atezolizumab group(14.3％),with only one case of grade 3 encephalitis.Conclusions:This RW study in China demonstrated improved clinical outcomes of atezolizumab along with EP for ES-SCLC,particularly in the chemosensitive population.These results align with the results of the IMpower133 study,although the impact of this treatment modality on OS warrants additional follow-up studies.
文献关键词：
中图分类号：
作者姓名：
Hanxiao Chen;Xiangjuan Ma;Jie Liu;Yu Yang;Yong Fang;Liping Wang;Jian Fang;Jun Zhao;Minglei Zhuo
作者机构：
Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department Ⅰ of Thoracic Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department Ⅱ of Thoracic Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Pneumology,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250117,China;Department of Oncology,the 2nd Affiliated Hospital of Harbin Medical University,Harbin 150001,China;Department of Oncology,Sir Run Run Shaw Hospital Zhejiang University School of Medicine,Hangzhou 310020,China;Department of Oncology,Baotou Cancer Hospital,Baotou 014030,China
文献出处：
引用格式：
[1]Hanxiao Chen;Xiangjuan Ma;Jie Liu;Yu Yang;Yong Fang;Liping Wang;Jian Fang;Jun Zhao;Minglei Zhuo-.Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small-cell lung cancer:A real-world,multicenter,retrospective,controlled study in China)[J].中国癌症研究（英文版）,2022(04):353-364
A类：
Atezolizumab,chemosensitive,IMpower133
B类：
Clinical,outcomes,atezolizumab,combination,etoposide,platinum,extensive,stage,small,cell,lung,cancer,real,multicenter,retrospective,controlled,study,China,Objective,along,chemotherapy,has,prolonged,survival,patients,ES,SCLC,worldwide,although,RW,data,are,lacking,This,was,designed,efficacy,clinical,plus,EP,Methods,Data,obtained,this,were,captured,from,six,oncology,units,five,medical,facilities,January,April,For,first,line,treatments,combined,alone,primarily,evaluated,progression,free,PFS,indicators,including,overall,OS,objective,response,ORR,patterns,adverse,events,AEs,assessed,Results,primary,analysis,included,whom,received,duration,months,confidence,interval,exceeded,that,Overall,hazard,particularly,among,undergoing,cycles,individuals,maintenance,disease,DCR,similar,between,two,groups,Because,incomplete,median,not,determined,either,Bone,marrow,suppression,most,common,detected,Immune,related,occurred,only,case,grade,encephalitis,Conclusions,demonstrated,improved,population,These,results,align,impact,modality,warrants,additional,follow,studies
AB值：
0.507379
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
